[go: up one dir, main page]

MA44969B1 - 5,6,7,8-tétrahydro[1,2,4]triazolo[4,3- a]pyridin-3(2h)-ones et 2,5,6,7-tétrahydro-3h-pyrrolo[2,1 -c][1,2,4]triazol-3-ones substituées et leur utilisation - Google Patents

5,6,7,8-tétrahydro[1,2,4]triazolo[4,3- a]pyridin-3(2h)-ones et 2,5,6,7-tétrahydro-3h-pyrrolo[2,1 -c][1,2,4]triazol-3-ones substituées et leur utilisation

Info

Publication number
MA44969B1
MA44969B1 MA44969A MA44969A MA44969B1 MA 44969 B1 MA44969 B1 MA 44969B1 MA 44969 A MA44969 A MA 44969A MA 44969 A MA44969 A MA 44969A MA 44969 B1 MA44969 B1 MA 44969B1
Authority
MA
Morocco
Prior art keywords
tetrahydro
ones
prophylaxis
treatment
diseases
Prior art date
Application number
MA44969A
Other languages
English (en)
Other versions
MA44969A (fr
Inventor
Klemens Lustig
Niels Lindner
Heinrich Meier
Dmitry Zubov
Martina SCHÄFER
Kersten Matthias Gericke
Damian Brockschnieder
Carsten TERJUNG
Dieter Moosmayer
Florian KÖLLING
Thomas Neubauer
Nicole BIBER
Jörg MEDING
Andreas Timmermann
Volker BADOCK
Hideki MIYATAKE ONDOZABAL
Stephen Moore
Alexander Schulz
Original Assignee
Bayer Pharma Aktiengesellschaft
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Priority claimed from PCT/EP2017/060900 external-priority patent/WO2017194459A1/fr
Publication of MA44969A publication Critical patent/MA44969A/fr
Publication of MA44969B1 publication Critical patent/MA44969B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente demande concerne de nouvelles 5,6,7,8-tétrahydro[1,2,4]triazolo[4,3-a]pyridine-3(2H)-ones et 2,5,6,7-tétrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones substituées, des méthodes pour leur synthèse, leur utilisation seule ou en combinaison pour le traitement et/ou la prophylaxie de maladies, et leur utilisation pour la fabrication de médicaments pour le traitement et/ou la prophylaxie de maladies, en particulier pour le traitement et/ou la prophylaxie de maladies, à leur utilisation seule ou en combinaison pour le traitement et/ou la prophylaxie de maladies, et à leur utilisation dans la fabrication de médicaments pour le traitement et/ou la prophylaxie de maladies, en particulier pour le traitement et/ou la prophylaxie de maladies pulmonaires inflammatoires.  
MA44969A 2016-05-09 2017-05-08 5,6,7,8-tétrahydro[1,2,4]triazolo[4,3- a]pyridin-3(2h)-ones et 2,5,6,7-tétrahydro-3h-pyrrolo[2,1 -c][1,2,4]triazol-3-ones substituées et leur utilisation MA44969B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2016168809 2016-05-09
EP17723053.9A EP3455224B1 (fr) 2016-05-09 2017-05-08 5,6,7,8-tétrahydro[1,2,4]triazolo[4,3- a]pyridin-3(2h)-ones et 2,5,6,7-tétrahydro-3h-pyrrolo[2,1 -c][1,2,4]triazol-3-ones substituées et leur utilisation
PCT/EP2017/060900 WO2017194459A1 (fr) 2016-05-09 2017-05-08 5,6,7,8-tétrahydro[1,2,4]triazolo[4,3- a]pyridin-3(2h)-ones et 2,5,6,7-tétrahydro-3h-pyrrolo[2,1 -c][1,2,4]triazol-3-ones substituées et leur utilisation

Publications (2)

Publication Number Publication Date
MA44969A MA44969A (fr) 2019-03-20
MA44969B1 true MA44969B1 (fr) 2024-06-28

Family

ID=65351627

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44969A MA44969B1 (fr) 2016-05-09 2017-05-08 5,6,7,8-tétrahydro[1,2,4]triazolo[4,3- a]pyridin-3(2h)-ones et 2,5,6,7-tétrahydro-3h-pyrrolo[2,1 -c][1,2,4]triazol-3-ones substituées et leur utilisation

Country Status (7)

Country Link
EP (1) EP3455224B1 (fr)
ES (1) ES2987656T3 (fr)
HR (1) HRP20240589T1 (fr)
HU (1) HUE066246T2 (fr)
MA (1) MA44969B1 (fr)
PL (1) PL3455224T3 (fr)
RS (1) RS65596B1 (fr)

Also Published As

Publication number Publication date
EP3455224B1 (fr) 2024-03-27
HRP20240589T1 (hr) 2024-07-19
RS65596B1 (sr) 2024-06-28
HUE066246T2 (hu) 2024-07-28
EP3455224A1 (fr) 2019-03-20
ES2987656T3 (es) 2024-11-15
MA44969A (fr) 2019-03-20
EP3455224C0 (fr) 2024-03-27
PL3455224T3 (pl) 2024-07-01

Similar Documents

Publication Publication Date Title
EA201990519A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-7-(1-АКРИЛОИЛПИПЕРИДИН-4-ИЛ)-2-(4-ФЕНОКСИФЕНИЛ)-4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРИМИДИН-3-КАРБОКСАМИДА, ЕЕ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЯ
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
DK3838274T3 (da) Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-derivat til brug til behandling af cns-lidelser
PH12018502359A1 (en) Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine-3(2h)-ones and 2,5,6,7-tetrahydro-3h-pyrrolo[2,1-c][1,2,4]triazol-3-ones, and use thereof
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
MX2018005694A (es) 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas.
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
MA35844B1 (fr) Pyrimidines et triazines annelées substituées et leur utilisation
EA201790259A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
MA42376A (fr) Dérivés d'oxopyridine substitués
TN2015000328A1 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
MA38365A1 (fr) Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante
UA120065C2 (uk) 4,6-ЗАМІЩЕНІ ПІРАЗОЛО[1,5-a]-ПІРАЗИНИ ЯК ІНГІБІТОРИ JAK-КІНАЗИ
PH12015501586A1 (en) 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
EA201891611A1 (ru) Роизводные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диазаспиро[4,5]декана
MA38925B1 (fr) Dérivés de phénylalanine substitués
IN2015DN03751A (fr)
WO2019016597A3 (fr) Protéines synthétiques et leurs utilisations thérapeutiques
MY182438A (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrohil elastase activity
CL2008002060A1 (es) Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.
MA44969B1 (fr) 5,6,7,8-tétrahydro[1,2,4]triazolo[4,3- a]pyridin-3(2h)-ones et 2,5,6,7-tétrahydro-3h-pyrrolo[2,1 -c][1,2,4]triazol-3-ones substituées et leur utilisation
JOP20190080A1 (ar) مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
ZA202100376B (en) Heterocyclic sulfonamide derivatives and pharmaceutical uses thereof